Research ArticleTheranostics
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
Wolfgang P. Fendler, Andreea D. Stuparu, Susan Evans-Axelsson, Katharina Lückerath, Liu Wei, Woosuk Kim, Soumya Poddar, Jonathan Said, Caius G. Radu, Matthias Eiber, Johannes Czernin, Roger Slavik and Ken Herrmann
Journal of Nuclear Medicine November 2017, 58 (11) 1786-1792; DOI: https://doi.org/10.2967/jnumed.117.193359
Wolfgang P. Fendler
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Andreea D. Stuparu
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Susan Evans-Axelsson
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Katharina Lückerath
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Liu Wei
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Woosuk Kim
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Soumya Poddar
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Jonathan Said
2Translational Pathology Core Laboratory, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA; and
Caius G. Radu
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Matthias Eiber
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Johannes Czernin
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Roger Slavik
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Ken Herrmann
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
3Universitätsklinikum Essen, Department of Nuclear Medicine, Essen, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 11
November 1, 2017
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
Wolfgang P. Fendler, Andreea D. Stuparu, Susan Evans-Axelsson, Katharina Lückerath, Liu Wei, Woosuk Kim, Soumya Poddar, Jonathan Said, Caius G. Radu, Matthias Eiber, Johannes Czernin, Roger Slavik, Ken Herrmann
Journal of Nuclear Medicine Nov 2017, 58 (11) 1786-1792; DOI: 10.2967/jnumed.117.193359
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
Wolfgang P. Fendler, Andreea D. Stuparu, Susan Evans-Axelsson, Katharina Lückerath, Liu Wei, Woosuk Kim, Soumya Poddar, Jonathan Said, Caius G. Radu, Matthias Eiber, Johannes Czernin, Roger Slavik, Ken Herrmann
Journal of Nuclear Medicine Nov 2017, 58 (11) 1786-1792; DOI: 10.2967/jnumed.117.193359
Jump to section
Related Articles
Cited By...
- Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors
- Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
- Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
- Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies
- Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
- Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
- Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy